Larynx preservation: What is the standard treatment?

Critical Reviews in Oncology/Hematology

Volumn 84, Issue SUPPL. 1, 2012, Pages e97-e105

  Horn, Samy ^a   Ozsahin, Mahmut ^b   Lefèbvre, Jean Louis ^a   Horiot, Jean Claude ^c   Lartigau, Eric ^a  

^a CENTRE OSCAR LAMBRET   (France)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^c CLINIQUE DE GENOLIER   (Switzerland)

Author keywords

Chemotherapy; Concurrent; Induction; Larynx preservation; Radiotherapy

Indexed keywords

CARBOPLATIN; CETUXIMAB; CISPLATIN; FLUOROURACIL; NIMORAZOLE; TAXANE DERIVATIVE;

ACNEIFORM RASH; BLOOD TOXICITY; CANCER CONTROL; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DISEASE SPECIFIC SURVIVAL; DRUG ERUPTION; DYSPHAGIA; FEBRILE NEUTROPENIA; FUNCTIONAL ASSESSMENT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HYPOPHARYNX CANCER; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; LARYNGECTOMY; LARYNX CANCER; LARYNX PRESERVATION; LOW DRUG DOSE; MOLECULARLY TARGETED THERAPY; MUCOSA INFLAMMATION; MUCOSAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; ORGAN PRESERVATION; OVERALL SURVIVAL; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIDE EFFECT; SKIN TOXICITY; SOCIAL ASPECT; SURVIVAL RATE; TREATMENT DURATION; TREATMENT RESPONSE; WEIGHT REDUCTION;

EID: 84871708273     PISSN: 10408428     EISSN: 18790461     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.11.008     Document Type: Review

References (39)

1. Daly-Schveitzer N. Cancerologie clinique 2008, Masson. 3rd ed.
2. Lefebvre J.L., Calais G. Larynx preservation, state of the art. Cancer Radiother 2005, 9(February (1)):37-41.
3. Bron L., Brossard E., Monnier P., Pasche P. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy and cricohyoidopexy for glottic and supraglottic carcinomas. Laryngoscope 2000, 110(April (4)):627-634.
4. Chevalier D., Laccourreye O., Brasnu D., Laccourreye H., Piquet J.J. Cricohyoidoepiglottopexy for glottic carcinoma with fixation or impaired motion of the true vocal cord: 5-year oncologic results with 112 patients. Ann Otol Rhinol Laryngol 1997, 106(May (5)):364-369.
5. Laccourreye O., Muscatello L., Laccourreye L., Naudo P., Brasnu D., Weinstein G. Supracricoid partial laryngectomy with cricohyoidoepiglottopexy for " early" glottic carcinoma classified as T1-T2N0 invading the anterior commissure. Am J Otolaryngol 1997, 18(November-December (6)):385-390.
6. Piquet J.J., Chevalier D. Subtotal laryngectomy with crico-hyoido-epiglotto-pexy for the treatment of extended glottic carcinomas. Am J Surg 1991, 162(October (4)):357-361.
7. Lefebvre J.L., Ang K.K., Larynx Preservation Consensus Panel Larynx preservation clinical trial guidelines. Head Neck 2009, 31(April (4)):429-441.
8. Dische S., Saunders M., Barrett A., Harvey A., Gibson D., Parmar M. A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol 1997, 44(August (2)):123-136.
9. Fu K.K., Pajak T.F., Trotti A., et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiation Oncology Biol Phys 2000, 48(1):7-16.
10. Overgaard J., Hansen H.S., Specht L., et al. Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6&7 randomised controlled trial. Lancet 2003, 362(September (9388)):933-940.
11. The Department of Veterans Affairs Laryngeal Cancer Study Group Induction chemotherapy plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991, 324(24):1685-1690.
12. Lefebvre J.L., Chevalier D., Luboinski B., Kirkpatrick A., Colette L., Sahmoud T. Larynx preservation in pyriform sinus cancer: preliminary results of a European organization for research and treatment of cancer phase III trial. EORTC head and neck cooperative group. J Natl Cancer Inst 1996, 88(13):890-899.
13. Richard J.M., Sancho-Garnier H., Pessey J.J., et al. Randomized trial of induction chemotherapy in larynx carcinoma. Oral Oncol 1998, 34(3):224-228.
14. Pignon J.P., Bourhis J., Domenge C., Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 2000, 355(9208):949-955.
15. Wendt T.G., Grabenbauer G.G., Rödel C.M., et al. Simultaneous radiochemotherapy versus radiotherapy alone in advanced head and neck cancer: a randomized multicenter study. J Clin Oncol 1998, 16:1318-1324.
16. Brizel D.M., Albers M.E., Fisher S.R., et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med 1998, 338:1798-1804.
17. Huguenin P., Beer K.T., Allal A., et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol 2004, 22(December (23)):4665-4673. [Erratum in: J Clin Oncol 2005;23(January (1)):248].
18. Adelstein D.J., Li Y., Adams G.L., et al. An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol 2003, 21(1):92-98.
19. Forastiere A.A., Goepfert H., Maor M., et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 2003, 349(22):2091-2098.
20. Forastiere A.A., Maor M., Weber R.S., et al. Long-term results of intergroup RTOG 91-11: a phase III trial to preserve the larynx - induction cisplatin/5-FU and radiation therapy versus concurrent cisplatin and radiation therapy versus radiation therapy. J Clin Oncol 2006, 24(No. 18S (June 20 Supplement)):5517.
21. Pignon J.P., Baujat B., Bourhis J. Individual patient data meta-analyses in head and neck carcinoma: what have we learnt. Cancer Radiother 2005, 9(February (1)):31-36.
22. Pignon J.P., Le Maître A., Maillard E., Bourrhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92(July (1)):4-14.
23. Vermorken J.B., Remenar E., van Herpen C., et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007, 357(17):1695-1704.
24. Posner M.R., Hershock D.M., Blajman C.R., et al. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med 2007, 357(17):1705-1715.
25. Calais G, Pointreau Y, Sire C, et al. Induction chemotherapy for larynx preservation. Updated results of the GORTEC 2000-01 randomized trial comparing docetaxel+cisplatin+fluorouracil (TPF) versus cisplatin+fluorouracil (PF). Proc European Cancer Conference ECCO 14 [Abstract 5500].
26. Pointreau Y., Garaud P., Chapet S., et al. Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 2009, 101(April (7)):498-506.
27. Lefebvre J.L., Rolland F., Tesselaar M., et al. Phase III randomized trial on larynx preservation comparing sequential vs. alternating chemotherapy and radiotherapy. J Natl Cancer Inst 2009, 101:142-152.
28. Hitt R., Grau J., Lopez-Pousa A., et al. Randomized phase II/III clinical trial of induction chemotherapy (ICT) with either cisplatin/5-fluorouracil (PF) or docetaxel/cisplatin/5-fluorouracil (TPF) followed by chemoradiotherapy (CRT) vs. crt alone for patients (pts) with unresectable locally advanced head and neck cancer (LAHNC). J Clin Oncol 2006, 24(No. 18S (June 20 Supplement)):5515.
29. Paccagnella A., Ghi M.G., Loreggian L., et al. Concomitant chemoradiotherapy versus induction docetaxel, cisplatin and 5 fluorouracil (TPF) followed by concomitant chemoradiotherapy in locally advanced head and neck cancer: a phase II randomized study. Ann Oncol 2010, 21(July (7)):1515-1522.
30. Bonner J.A., Harari P.M., Giralt J., et al. Improved preservation of larynx with the addition of cetuximab to radiation for cancer of the larynx and hypopharynx. Proc Am Soc Clin Oncol 2005, [J Clin Oncol 2005;16s(23), abstract 5533; p 508s].
31. Bonner J.A., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010, 11(January (1)):21-28.
32. Bonner J., Harari P.M., Giralt J., et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354(February (6)):567-578.
33. Lefebvre J.L., Pointreau Y., Rolland F., et al. Sequential chemoradiotherapy (SCRT) for larynx preservation (LP): preliminary results of the randomized phase II TREMPLIN study. J Clin Oncol 2009, 27(No. 15S (May 20 Supplement)):6010.
34. Fayette J. La chimiothérapie d'induction dans les cancers ORL avancés: indication, gestion pratique et stratégies thérapeutiques. http://www.fom-k.net/site/-Cancer-des-VADS-.
35. Guerrero Urbano T., Clark C.H., Hansen V.N., et al. A phase I study of dose-escalated chemoradiation with accelerated intensity modulated radiotherapy in locally advanced head and neck cancer. Radiother Oncol 2007, 85(October (1)):36-41.
36. Studer G., Lütolf U.M., Davis J.B., Glanzmann C. IMRT in hypopharyngeal tumors. Strahlenther Onkol 2006, 182(June (6)):331-335.
37. Machtay M., Moughan J., Trotti A., et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: an RTOG analysis. J Clin Oncol 2008, 26(July (21)):3582-3589.
38. Calais G., Ceruse P., Chevalier D., Guigay J., Lefebvre J.L. Guide pratique de prise en charge des tumeurs de la tête et du cou. Le larynx. Publiclin 2009.
39. Lefebvre J.L., Ang K.K., Larynx Preservation Consensus Panel Larynx preservation clinical trial design: key issues and recommendations - a consensus panel summary. Int J Radiat Oncol Biol Phys 2009, 73(April (5)):1293-1303.